T. Rowe Price Associates
TTPH

T. Rowe Price Associates’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

T. Rowe Price Associates’s Portfolio TTPH Stock Details TTPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-11,430
Closed -$32K – 2585
2019
Q4 		$32K Buy
+11,430
New +$36.7K ﹤0.01% 2508
2019
Q3 		– Sell
-8,180
Closed -$79K – 2557
2019
Q2 		$79K Sell
8,180
-43
-0.5% -$791 ﹤0.01% 2495
2019
Q1 		$220K Buy
8,223
+10
+0.1% +$254 ﹤0.01% 2384
2018
Q4 		$186K Buy
8,213
+1,765
+27% +$69K ﹤0.01% 2423
2018
Q3 		$356K Buy
6,448
+3,133
+95% +$200K ﹤0.01% 2285
2018
Q2 		$237K Buy
3,315
+5
+0.2% +$353 ﹤0.01% 2407
2018
Q1 		$203K Sell
3,310
-885
-21% -$77.7K ﹤0.01% 2412
2017
Q4 		$529K Buy
4,195
+2,755
+191% +$353K ﹤0.01% 2072
2017
Q3 		$197K Buy
1,440
+600
+71% +$80.3K ﹤0.01% 2415
2017
Q2 		$120K Hold
840
– – ﹤0.01% 2459
2017
Q1 		$154K Hold
840
– – ﹤0.01% 2434
2016
Q4 		$68K Sell
840
-5
-0.6% -$396 ﹤0.01% 2504
2016
Q3 		$65K Hold
845
– – ﹤0.01% 2486
2016
Q2 		$73K Buy
845
+5
+0.6% +$458 ﹤0.01% 2462
2016
Q1 		$78K Hold
840
– – ﹤0.01% 2440
2015
Q4 		$169K Buy
+840
New +$168K ﹤0.01% 2338

Other funds holding TTPH

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

T. Rowe Price Associates's TTPH Position: Q1 2020 in Review

T. Rowe Price Associates sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q1 2020, closing a stake of 11,430 shares — an estimated $32K sold.

T. Rowe Price Associates first reported a position in TTPH in Q4 2015 and held it in 16 quarters. The position peaked at $529K in Q4 2017. 25 funds tracked by Wall St. Rank hold TTPH as of Q1 2020.

  • T. Rowe Price Associates reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
  • T. Rowe Price Associates sold 11,430 Tetraphase Pharmaceuticals, Inc. shares in Q1 2020, an estimated $32K.
  • T. Rowe Price Associates first reported a position in Tetraphase Pharmaceuticals, Inc. in Q4 2015 and held it in 16 quarters.
  • T. Rowe Price Associates's Tetraphase Pharmaceuticals, Inc. position peaked at $529K in Q4 2017.
  • 25 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q1 2020.

Based on T. Rowe Price Associates's 13F filing for Q1 2020, filed 15 May 2020.